Transaction DateRecipientSharesTypePriceValue
3rd November 2020David J. Arthur4,879Grant/award etc.$0.56$2,737.12
3rd November 2020Mark J Rosenblum4,723Grant/award etc.$0.56$2,649.60
21st August 2020Arnold C Hanish4,000Open or private purchase$0.98$3,920.00
19th August 2020David J. Arthur1,000Open or private purchase$1.01$1,010.00
19th August 2020David J. Arthur1,000Open or private purchase$1.01$1,010.00
17th August 2020Mark J Rosenblum5,000Open or private purchase$1.00$5,000.00
19th February 2020Mark J Rosenblum2,000Open or private purchase$0.95$1,900.00
18th February 2020Scott Jordan11,300Open or private purchase$0.90$10,170.00
13th February 2020Mark J Rosenblum5,000Open or private purchase$0.86$4,295.00
11th February 2020Arnold C Hanish4,350Open or private purchase$1.15$5,002.50
Flex Pharma
Flex Pharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.

Ticker: FLKS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1615219
Employees: 4
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $7 M (93%)
Receivables, Net, Current: $2 M (0%)
Other Assets, Current: $119 Th (-12%)
Assets, Current: $9 M (100%)
Property, Plant and Equipment, Net: $19 Th (-25%)
Other Assets, Noncurrent: $280 Th (-9%)
Assets: $19 M (33%)
Accounts Payable, Current: $1 M (-35%)
Liabilities: $2 M (-48%)
Common Stock, Value, Issued: $1 Th (224%)
Common Stock, Shares, Issued: $15 M (223%)
Retained Earnings (Accumulated Deficit): $16 M (32%)
Stockholders' Equity (Parent): $17 M (0%)
Liabilities and Equity: $19 M (33%)
Revenue: $1 M (-47%)
Research and Development: $1 M (-53%)
General and Administrative Expenses: $2 M (-52%)
Operating Income/Loss: $2 M (-55%)